Humasis Co. Ltd.

KOSDAQ 205470.KQ

Humasis Co. Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 13.57

Humasis Co. Ltd. Price to Sales Ratio (P/S) is 13.57 on January 14, 2025, a -4.33% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Humasis Co. Ltd. 52-week high Price to Sales Ratio (P/S) is 24.25 on August 19, 2024, which is 78.72% above the current Price to Sales Ratio (P/S).
Humasis Co. Ltd. 52-week low Price to Sales Ratio (P/S) is 11.28 on December 27, 2024, which is -16.83% below the current Price to Sales Ratio (P/S).
Humasis Co. Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 14.17.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KOSDAQ: 205470.KQ

Humasis Co. Ltd.

CEO	Sung-gon Kim
IPO Date	Sept. 27, 2017
Location	South Korea
Headquarters	504, Shinwon Vision Tower
Employees	105
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.

Key trends

Past 5 years